Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495309 | 0.87 | SLC6A3 (0.30) | SLC6A3 | |
| SCHEMBL13495363 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL13495368 | 0.77 | — | — | |
| SCHEMBL13495335 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13495365 | 0.74 | ALDH1A1 (0.38) | KDM4EALDH1A1LMNA | |
| SCHEMBL13495373 | 0.72 | ALDH1A1 (0.37) | KDM4EALDH1A1LMNA | |
| SCHEMBL13495337 | 0.69 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL13495332 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13496205 | 0.68 | — | — | |
| SCHEMBL13495336 | 0.65 | HSD17B10 (0.37) | ALDH1A1LMNATP53NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329377-B2 | Imide compound and chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329377-B2 | Imide compound and chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | IGF1R, CCNA1, MYC | SLC6A3 4357/4885KDM4E 1539/4885ALDH1A1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.